Related references
Note: Only part of the references are listed.Pancreatic Cancer Clinical Trials and Accrual in the United States
William A. Hoos et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting p53 by small molecules in hematological malignancies
Manujendra N. Saha et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation
Noriko Kobayashi et al.
JOURNAL OF OVARIAN RESEARCH (2013)
Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells
Rosa Linda Messina et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo
Wenjie Bao et al.
CELL CYCLE (2011)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma
Jong-Lyel Roh et al.
ORAL ONCOLOGY (2011)
PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells
Debora Russo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
K. G. Wiman
ONCOGENE (2010)
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Jennifer P. Morton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting p53 for novel anticancer therapy
Zhen Wang et al.
TRANSLATIONAL ONCOLOGY (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Pancreatic cancer
Anirban Maitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
Kageaki Kuribayashi et al.
CANCER BIOLOGY & THERAPY (2008)
Pancreatic cancer stem cells: Implications for the treatment of pancreatic cancer
Diane M. Simeone
CLINICAL CANCER RESEARCH (2008)
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions
Marketa Hermanova et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2008)
Pancreatic cancer: Pathogenesis, prevention and treatment
Fazlul H. Sarkar et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
Endoplasmic reticulum stress-induced apoptosis - Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53
JZ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
VJN Bykov et al.
ONCOGENE (2005)
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
H Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription
JE Chipuk et al.
CANCER CELL (2003)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Share Paper
